Cancer is an important challenge for which personalized molecular medicine shows great promise. Recent advances in immunotherapy and genetic testing have been proposed to help transform care from one-size-fits-all to a highly specialized range of options that could be adapted to fit an individual’s molecular features. However, we are still far from understanding and navigating cancer. In fact, many promising research projects that reveal new targets and promising strategies that work on animal models fail in clinical trials. While generating data has been increasingly accessible, the challenge is now in integration and extracting insights from this data. A multi-omics approach based on big data analyses could lead to substantial advances in cancer treatment.